<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02633358</url>
  </required_header>
  <id_info>
    <org_study_id>CMUH104-REC3-058</org_study_id>
    <nct_id>NCT02633358</nct_id>
  </id_info>
  <brief_title>Anti-inflammatory Effect of Therapeutic Hypothermia in Out-hospital Cardiac Arrest Patients With Cardiogenic Shock</brief_title>
  <official_title>Anti-inflammatory Effect of Therapeutic Hypothermia in Out-hospital Cardiac Arrest Patients With Cardiogenic Shock Via Interleukin-6 Trans-signaling</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China Medical University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute myocardial infarction complicated with cardiogenic shock trigger IL-6, the strong
      inflammatory response, result in multiple organ failure, even death.

      While therapeutic hypothermia,to expect the possibility of anti-inflammatory effect via IL-6
      bi-phasic effect and IL-10 , to improve the multiple organ failure, to increase survival rate
      and well cerebral performance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite emergency coronary revascularization coupled with medical stabilization, intra-aortic
      balloon pump have significantly improved survival in patients with cardiogenic shock
      complicating acute myocardial infarction, mortality still remains excessively high, being
      actually about 30-50%. Future research should focus on new therapeutic strategies, aimed to
      further decrease mortality rate of these patients or improve possible hospitalization and
      prognosis.

      Heart pumping failure result in cardiogenic shock. Increased LA filling pressure result in
      acute pulmonary edema, hypoxemic respiratory failure, even congestive kidney and congestive
      liver. Decreased stroke volume result in hypoperfusion obviously direct induce acute renal
      failure, disturbance consciousness and lactate accumulation, even, shock liver. Multiple
      organ failure is the major mortality in the patients suffered from cardiogenic shock after
      acute myocardial infarction.

      Cardiogenic shock remains the leading cause of death in patients hospitalized for myocardial
      infarction . Systemic inflammation , especially endovascular Interleukin-6, triggered by
      Tumor necrosis factor-alfa and Interleukin-1 beta result in inappropriate vasodilatation is
      observed in many patients with cardiogenic shock and may contribute to an excess mortality
      rate. In recent study, interleukin-6 represented a reliable independent early prognostic
      marker of 30-day mortality.

      Therapeutic hypothermia (34℃) increase stroke volume, reduce muscle oxygen consumption and
      enhance anti-inflammatory action . The mechanism of anti-inflammatory effect for therapeutic
      hypothermia in cardiogenic shock is still unclear, need to further study in clinical trial.
      Furthermore, this study will provide new strategy to increase survival rate in cardiogenic
      shock.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1, 2015</start_date>
  <completion_date type="Actual">August 18, 2018</completion_date>
  <primary_completion_date type="Actual">August 18, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival Rate - Number of Participants Alive</measure>
    <time_frame>90 days after enrollment</time_frame>
    <description>Survival rate according to the number of participants alive in the 90 days after enrollment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurologic Outcome - Number of Participants</measure>
    <time_frame>90 days after enrollment</time_frame>
    <description>Neurological outcome according to Cerebral performance Category scales: scales 1-2 in favor of favorable neurological outcome; scales 3-5 in favor of poor neurological outcome including severe cerebral disability, coma or vegetative state, brain death.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Interleukin-6 - the Plasma Level of Participants</measure>
    <time_frame>between 6 and 24 hours after enrollment.</time_frame>
    <description>IL-6 level change</description>
  </other_outcome>
  <other_outcome>
    <measure>Interleukin-6/Soluble Interleukin-6 Receptor Complex - the Plasma Level of Participants</measure>
    <time_frame>between 6 and 24 hours after enrollment</time_frame>
    <description>Interleukin-6/soluble Interleukin-6 receptor complex plasma level hint the pro-inflammatory pathway via Interleukin-6 trans-signaling</description>
  </other_outcome>
  <other_outcome>
    <measure>Soluble Interleukin-6 Receptor - the Plasma Level of Participants</measure>
    <time_frame>between 6 and 24 hours after enrollment</time_frame>
    <description>Check the soluble Interleukin-6 plasma level at 6 hours and 24 hours after enrollment</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">141</enrollment>
  <condition>Cardiac Arrest</condition>
  <arm_group>
    <arm_group_label>Therapeutic hypothermia group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anti-inflammatory effect of therapeutic hypothermia. The hypothesis is anti-inflammatory effect triggered by IL-6 trans-signaling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No therapeutic hypothermia for controlled data.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Therapeutic hypothermia group</intervention_name>
    <description>Therapeutic hypothermia</description>
    <arm_group_label>Therapeutic hypothermia group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18-100 years

          -  Cardiogenic sock including initial lactate level &gt;18 mg/dL, necessary of vasopressor
             to keep mean artery pressure &gt;65mmHg after adequate fluid supply, and signs of reduced
             cardiac output including disturbance consciousness, cold limbs, decreased urine
             output, acute pulmonary congestion and so on.

        Exclusion Criteria:

          -  Patient or family refuse

          -  Metastatic cancer

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Da-Long Chen, Master</last_name>
    <role>Study Director</role>
    <affiliation>Chnia Medical University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Schmitt KR, Tong G, Berger F. Mechanisms of hypothermia-induced cell protection in the brain. Mol Cell Pediatr. 2014 Dec;1(1):7. doi: 10.1186/s40348-014-0007-x. Epub 2014 Dec 1.</citation>
    <PMID>26567101</PMID>
  </reference>
  <reference>
    <citation>Bro-Jeppesen J, Kjaergaard J, Stammet P, Wise MP, Hovdenes J, Åneman A, Horn J, Devaux Y, Erlinge D, Gasche Y, Wanscher M, Cronberg T, Friberg H, Wetterslev J, Pellis T, Kuiper M, Nielsen N, Hassager C; TTM-Trial Investigators. Predictive value of interleukin-6 in post-cardiac arrest patients treated with targeted temperature management at 33 °C or 36 °C. Resuscitation. 2016 Jan;98:1-8. doi: 10.1016/j.resuscitation.2015.10.009. Epub 2015 Oct 23.</citation>
    <PMID>26525271</PMID>
  </reference>
  <reference>
    <citation>Forkmann M, Kolschmann S, Holzhauser L, Ibrahim K, Guenther M, Christoph M, Fuhrmann JT, Boscheri A, Schmeiβer A, Strasser RH, Wunderlich C. Target temperature management of 33 degrees C exerts beneficial haemodynamic effects after out-of-hospital cardiac arrest. Acta Cardiol. 2015 Aug;70(4):451-9.</citation>
    <PMID>26455248</PMID>
  </reference>
  <reference>
    <citation>Nobile L, Lamanna I, Fontana V, Donadello K, Dell'anna AM, Creteur J, Vincent JL, Pappalardo F, Taccone FS. Greater temperature variability is not associated with a worse neurological outcome after cardiac arrest. Resuscitation. 2015 Nov;96:268-74. doi: 10.1016/j.resuscitation.2015.09.004. Epub 2015 Sep 16.</citation>
    <PMID>26386374</PMID>
  </reference>
  <reference>
    <citation>Bro-Jeppesen J, Kjaergaard J, Wanscher M, Nielsen N, Friberg H, Bjerre M, Hassager C. Systemic Inflammatory Response and Potential Prognostic Implications After Out-of-Hospital Cardiac Arrest: A Substudy of the Target Temperature Management Trial. Crit Care Med. 2015 Jun;43(6):1223-32. doi: 10.1097/CCM.0000000000000937.</citation>
    <PMID>25756419</PMID>
  </reference>
  <reference>
    <citation>Dankiewicz J, Nielsen N, Annborn M, Cronberg T, Erlinge D, Gasche Y, Hassager C, Kjaergaard J, Pellis T, Friberg H. Survival in patients without acute ST elevation after cardiac arrest and association with early coronary angiography: a post hoc analysis from the TTM trial. Intensive Care Med. 2015 May;41(5):856-64. doi: 10.1007/s00134-015-3735-z. Epub 2015 Mar 24. Erratum in: Intensive Care Med. 2015 Jun;41(6):1177.</citation>
    <PMID>25800582</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>December 8, 2015</study_first_submitted>
  <study_first_submitted_qc>December 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2015</study_first_posted>
  <results_first_submitted>August 19, 2018</results_first_submitted>
  <results_first_submitted_qc>May 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 23, 2019</results_first_posted>
  <last_update_submitted>July 28, 2019</last_update_submitted>
  <last_update_submitted_qc>July 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute myocardial infarction, cardiogenic shock</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Arrest</mesh_term>
    <mesh_term>Shock, Cardiogenic</mesh_term>
    <mesh_term>Hypothermia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 25, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT02633358/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: 2015 Jan. to 2018 Apr. Types of location: Cardiac intensive care units, China Medical University Hospital, Taichung, Taiwan</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Therapeutic Hypothermia</title>
          <description>Anti-inflammatory effect of therapeutic hypothermia. The hypothesis is anti-inflammatory effect triggered by IL-6 trans-signaling
Therapeutic hypothermia: Therapeutic hypothermia</description>
        </group>
        <group group_id="P2">
          <title>Non-hypothermia</title>
          <description>Control group for non-hypothermia. Anti-inflammatory effect of therapeutic hypothermia. The hypothesis is anti-inflammatory effect triggered by IL-6 trans-signaling</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Total 141 patients involved in this study. 87 patients divided in the therapeutic hypothermia group and 54 patients divided in the control group.</population>
      <group_list>
        <group group_id="B1">
          <title>Therapeutic Hypothermia</title>
          <description>Anti-inflammatory effect of therapeutic hypothermia. The hypothesis is anti-inflammatory effect triggered by IL-6 trans-signaling
Therapeutic hypothermia: Therapeutic hypothermia</description>
        </group>
        <group group_id="B2">
          <title>Non-Hypothermia</title>
          <description>Control group for non-hypothermia. Anti-inflammatory effect of therapeutic hypothermia. The hypothesis is anti-inflammatory effect triggered by IL-6 trans-signaling</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="87"/>
            <count group_id="B2" value="54"/>
            <count group_id="B3" value="141"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Chinese in Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japanese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Survival Rate - Number of Participants Alive</title>
        <description>Survival rate according to the number of participants alive in the 90 days after enrollment.</description>
        <time_frame>90 days after enrollment</time_frame>
        <population>Randomized divided to two groups including therapeutic hypothermia group and non-hypothermia group</population>
        <group_list>
          <group group_id="O1">
            <title>Therapeutic Hypothermia</title>
            <description>Anti-inflammatory effect of therapeutic hypothermia. The hypothesis is anti-inflammatory effect triggered by IL-6 trans-signaling
Therapeutic hypothermia: Therapeutic hypothermia</description>
          </group>
          <group group_id="O2">
            <title>Non-hypothermia</title>
            <description>Control group for non-hypothermia.
Anti-inflammatory effect of therapeutic hypothermia. The hypothesis is anti-inflammatory effect triggered by IL-6 trans-signaling</description>
          </group>
        </group_list>
        <measure>
          <title>Survival Rate - Number of Participants Alive</title>
          <description>Survival rate according to the number of participants alive in the 90 days after enrollment.</description>
          <population>Randomized divided to two groups including therapeutic hypothermia group and non-hypothermia group</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Survival</title>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-survival</title>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Therapeutic hypothermia group compare with control group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Therapeutic hypothermia need to have superiority in the survival rate after 90 days</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value less than 0.05 means significant data</p_value_desc>
            <method>Chi-squared</method>
            <method_desc>Test method for proportional data</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.41</ci_lower_limit>
            <ci_upper_limit>0.82</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurologic Outcome - Number of Participants</title>
        <description>Neurological outcome according to Cerebral performance Category scales: scales 1-2 in favor of favorable neurological outcome; scales 3-5 in favor of poor neurological outcome including severe cerebral disability, coma or vegetative state, brain death.</description>
        <time_frame>90 days after enrollment</time_frame>
        <population>Randomized divided to two groups including therapeutic hypothermia group and non-hypothermia group</population>
        <group_list>
          <group group_id="O1">
            <title>Therapeutic Hypothermia</title>
            <description>Anti-inflammatory effect of therapeutic hypothermia. The hypothesis is anti-inflammatory effect triggered by IL-6 trans-signaling
Therapeutic hypothermia: Therapeutic hypothermia</description>
          </group>
          <group group_id="O2">
            <title>Non-hypothermia</title>
            <description>Control group for non-hypothermia.
Anti-inflammatory effect of therapeutic hypothermia. The hypothesis is anti-inflammatory effect triggered by IL-6 trans-signaling</description>
          </group>
        </group_list>
        <measure>
          <title>Neurologic Outcome - Number of Participants</title>
          <description>Neurological outcome according to Cerebral performance Category scales: scales 1-2 in favor of favorable neurological outcome; scales 3-5 in favor of poor neurological outcome including severe cerebral disability, coma or vegetative state, brain death.</description>
          <population>Randomized divided to two groups including therapeutic hypothermia group and non-hypothermia group</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Favorable neurologic outcome</title>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Poor neurologic outcome</title>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Therapeutic hypothermia group compare with control group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Therapeutic hypothermia nee to have superiority in neurological outcome in the 90 days after enrollment.</non_inferiority_desc>
            <p_value>0.04</p_value>
            <p_value_desc>P value less than 0.05 means significant date</p_value_desc>
            <method>Chi-squared</method>
            <method_desc>Test method for proportional data</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Interleukin-6 - the Plasma Level of Participants</title>
        <description>IL-6 level change</description>
        <time_frame>between 6 and 24 hours after enrollment.</time_frame>
        <population>Randomized divided to two groups including therapeutic hypothermia and non-hypothermia group</population>
        <group_list>
          <group group_id="O1">
            <title>Therapeutic Hypothermia</title>
            <description>Anti-inflammatory effect of therapeutic hypothermia. The hypothesis is anti-inflammatory effect triggered by IL-6 trans-signaling
Therapeutic hypothermia: Therapeutic hypothermia</description>
          </group>
          <group group_id="O2">
            <title>Non-hypothermia</title>
            <description>Control group for non-hypothermia.
Anti-inflammatory effect of therapeutic hypothermia. The hypothesis is anti-inflammatory effect triggered by IL-6 trans-signaling</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin-6 - the Plasma Level of Participants</title>
          <description>IL-6 level change</description>
          <population>Randomized divided to two groups including therapeutic hypothermia and non-hypothermia group</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 hours after enrollment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2064.1" spread="178.2"/>
                    <measurement group_id="O2" value="2392.4" spread="181.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours after enrollment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="914.5" spread="187.8"/>
                    <measurement group_id="O2" value="5125.0" spread="592.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>P-value less than 0.05 is statistical significance.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Interleukin-6/Soluble Interleukin-6 Receptor Complex - the Plasma Level of Participants</title>
        <description>Interleukin-6/soluble Interleukin-6 receptor complex plasma level hint the pro-inflammatory pathway via Interleukin-6 trans-signaling</description>
        <time_frame>between 6 and 24 hours after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Therapeutic Hypothermia</title>
            <description>Anti-inflammatory effect of therapeutic hypothermia. The hypothesis is anti-inflammatory effect triggered by IL-6 trans-signaling
Therapeutic hypothermia: Therapeutic hypothermia</description>
          </group>
          <group group_id="O2">
            <title>Non-hypothermia</title>
            <description>Control group for non-hypothermia. Anti-inflammatory effect of therapeutic hypothermia. The hypothesis is anti-inflammatory effect triggered by IL-6 trans-signaling</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin-6/Soluble Interleukin-6 Receptor Complex - the Plasma Level of Participants</title>
          <description>Interleukin-6/soluble Interleukin-6 receptor complex plasma level hint the pro-inflammatory pathway via Interleukin-6 trans-signaling</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 hours after enrollment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169.1" spread="7.6"/>
                    <measurement group_id="O2" value="188.1" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours after enrollment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207.8" spread="14.6"/>
                    <measurement group_id="O2" value="319.7" spread="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>P-value less than 0.05 is statistical significance.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Soluble Interleukin-6 Receptor - the Plasma Level of Participants</title>
        <description>Check the soluble Interleukin-6 plasma level at 6 hours and 24 hours after enrollment</description>
        <time_frame>between 6 and 24 hours after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Therapeutic Hypothermia</title>
            <description>Anti-inflammatory effect of therapeutic hypothermia. The hypothesis is anti-inflammatory effect triggered by IL-6 trans-signaling
Therapeutic hypothermia: Therapeutic hypothermia</description>
          </group>
          <group group_id="O2">
            <title>Non-hypothermia</title>
            <description>Control group for non-hypothermia. Anti-inflammatory effect of therapeutic hypothermia. The hypothesis is anti-inflammatory effect triggered by IL-6 trans-signaling</description>
          </group>
        </group_list>
        <measure>
          <title>Soluble Interleukin-6 Receptor - the Plasma Level of Participants</title>
          <description>Check the soluble Interleukin-6 plasma level at 6 hours and 24 hours after enrollment</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 hours after enrollment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.6" spread="1.6"/>
                    <measurement group_id="O2" value="37.9" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours after enrollment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.9" spread="1.3"/>
                    <measurement group_id="O2" value="35.7" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>P-value less then 0.05 is statistical significance.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>90-day follow up</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Therapeutic Hypothermia</title>
          <description>Adverse events including ventricular arrhythmia, active bleeding, death due to lower core temperature less than 32 degree Celsius.</description>
        </group>
        <group group_id="E2">
          <title>Non-Hypothermia</title>
          <description>Adverse events including ventricular arrhythmia, active bleeding, death due to lower core temperature less than 32 degree Celsius.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Severe cerebral disability</sub_title>
                <description>Severe cerebral disability</description>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="87"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Coma or vegetative state</sub_title>
                <description>Coma or vegetative state</description>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="87"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Brain death</sub_title>
                <description>Brain death</description>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="87"/>
                <counts group_id="E2" events="34" subjects_affected="34" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Pregnancy, terminal and metastatic cancer, uncontrolled bleeding and family refuse inform consent had been excluded.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Da-Long Chen, director of cardiac intensive care unit</name_or_title>
      <organization>China Medical University Hospital, Taichung, Taiwan</organization>
      <phone>0952122027</phone>
      <email>my686chen@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

